Anavex Life Sciences Corp (AVXL)

[Investor2014]

1. Let' assume A2-73 is approved and that the MoA as suggested is disease modifying changing the course of AD and that, as we have heard on, the on, then off and on drug again shows renewed efficacy, as well the potential prophylactic use means that A2-73 may be applicable for long term use. We don't know this to be the case yet and I'd advise leaving those ideas in check until perhaps we see an approval - see points 2 and 3
2. First of all the likelihood that symptoms disappear with Donanemab or the other mabs is low to non-existent. Like the other mabs the best hope is a slower decline and not a halt or reversal of dementia symptoms. Such a slowing of decline overall for the trial population is all we have seen form A2-73 too based on results published so far. How many and under what condition might actually improve on A2-73 is tbd
3. I doubt reappearance of amyloid plaque and then getting treated with one of the mabs again would be a practical or useful approach. These drugs for some small subset of AD patients just slows down the decline in ways that neither the patient or family is likely to notice very much